Paul Geyer - Neovasc Chairman of the Board
| NVCNDelisted Stock | USD 30.03 0.00 0.00% |
Chairman
Mr. Paul L. Geyer is Director of the Company. He resigned as President and Chief Executive Officer of the Company. Mr. Geyer has served on the Companys board since November 2, 2000 and is a resident of British Columbia, Canada. In addition, Mr. Geyer is a member of the Companys audit committee. Since June 2009, Mr. Geyer was Chief Executive Officer of LightIntegra Technology Inc., a private medical device company focused on the development of the ThromboLux technology, used as a point of care device to determine platelet quality for blood transfusions. Mr. Geyer is an active angel investor and supporter of local technology and life sciences firms. He is on the board of directors of the BC Technology Industry Association, and is a director for several private companies. He served previously on the board of directors for the Medical Device Development Center and MEDEC, the association representing medical device companies across Canada. Mr. Geyer is Chairman of the Board of BC Social Venture Partners. In April 2011, Mr. Geyer was awarded the LifeSciences BC Leadership Award. Mr. Geyer graduated with a B.A.Sc. in electrical engineering from the University of British Columbia and has taken post graduate programs in finance and biomedical engineering. Mr. Geyer has completed a Certified Director program at the Anderson Graduate School of Management at the University of California, Los Angeles. since 2018.
| Age | 45 |
| Tenure | 6 years |
| Phone | 604 270 4344 |
| Web | https://www.neovasc.com |
Neovasc Management Efficiency
The company has return on total asset (ROA) of (0.3295) % which means that it has lost $0.3295 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7825) %, meaning that it created substantial loss on money invested by shareholders. Neovasc's management efficiency ratios could be used to measure how well Neovasc manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 12.63 M in liabilities with Debt to Equity (D/E) ratio of 0.34, which is about average as compared to similar companies. Neovasc has a current ratio of 9.47, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Neovasc until it has trouble settling it off, either with new capital or with free cash flow. So, Neovasc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Neovasc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Neovasc to invest in growth at high rates of return. When we think about Neovasc's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | CHAIRMAN Age | ||
| Marilyn Nelson | Inspire Medical Systems | 81 | |
| Olivier Bohuon | Smith Nephew plc | 58 | |
| Zackary Irani | Biomerica | 58 | |
| Terry Schlotterback | Orthopediatrics Corp | 62 | |
| Al Kraus | Cytosorbents Crp | 69 | |
| Bruce Stroever | Bone Biologics Corp | 66 | |
| Stephen DeFalco | Senseonics Holdings | 55 | |
| Don Hankey | Bone Biologics Corp | N/A | |
| Roberto Quarta | Smith Nephew plc | 67 | |
Management Performance
| Return On Equity | -0.78 | |||
| Return On Asset | -0.33 |
Neovasc Leadership Team
Elected by the shareholders, the Neovasc's board of directors comprises two types of representatives: Neovasc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neovasc. The board's role is to monitor Neovasc's management team and ensure that shareholders' interests are well served. Neovasc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neovasc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, CFO Sec | ||
| Fred Colen, President CEO | ||
| Steven Rubin, Independent Director | ||
| William ONeill, Independent Director | ||
| Alexei Marko, CEO and Non-Independent Director | ||
| Sarah Gallagher, VP Affairs | ||
| Paul Geyer, Chairman of the Board | ||
| Vicki Bebeau, VP of Clinical Affairs | ||
| Brian McPherson, COO and President of Neovasc Surgical | ||
| Fredericus Colen, CEO Pres | ||
| Christopher Clark, CFO, Corporate Secretary | ||
| Douglas Janzen, Independent Director | ||
| Jane Hsiao, Independent Director | ||
| John Panton, Chief Officer | ||
| Randy Lane, VP of RandD | ||
| William Little, Chief Officer |
Neovasc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neovasc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 8.96 M | |||
| Shares Outstanding | 2.76 M | |||
| Shares Owned By Insiders | 3.69 % | |||
| Shares Owned By Institutions | 7.87 % | |||
| Number Of Shares Shorted | 21.32 K | |||
| Price To Earning | 0.21 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 9.37 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Neovasc information on this page should be used as a complementary analysis to other Neovasc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Neovasc Stock
If you are still planning to invest in Neovasc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neovasc's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |